130 related articles for article (PubMed ID: 31772328)
1. Initiation of human mammary cell tumorigenesis by mutant KRAS requires YAP inactivation.
Lefort S; Tan S; Balani S; Rafn B; Pellacani D; Hirst M; Sorensen PH; Eaves CJ
Oncogene; 2020 Feb; 39(9):1957-1968. PubMed ID: 31772328
[TBL] [Abstract][Full Text] [Related]
2. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
3. The ubiquitin E3 ligase ITCH enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway.
Salah Z; Itzhaki E; Aqeilan RI
Oncotarget; 2014 Nov; 5(21):10886-900. PubMed ID: 25350971
[TBL] [Abstract][Full Text] [Related]
4. Deregulation of the Hippo pathway in mouse mammary stem cells promotes mammary tumorigenesis.
Li H; Gumbiner BM
Mamm Genome; 2016 Dec; 27(11-12):556-564. PubMed ID: 27601049
[TBL] [Abstract][Full Text] [Related]
5. Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pancreatic ductal adenocarcinoma in KrasG12D mice.
Hao F; Xu Q; Wang J; Yu S; Chang HH; Sinnett-Smith J; Eibl G; Rozengurt E
PLoS One; 2019; 14(5):e0216603. PubMed ID: 31100067
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity.
Adhikari H; Kattan WE; Kumar S; Zhou P; Hancock JF; Counter CM
Nat Commun; 2021 Sep; 12(1):5248. PubMed ID: 34504076
[TBL] [Abstract][Full Text] [Related]
7. PI3K Positively Regulates YAP and TAZ in Mammary Tumorigenesis Through Multiple Signaling Pathways.
Zhao Y; Montminy T; Azad T; Lightbody E; Hao Y; SenGupta S; Asselin E; Nicol C; Yang X
Mol Cancer Res; 2018 Jun; 16(6):1046-1058. PubMed ID: 29545474
[TBL] [Abstract][Full Text] [Related]
8. TRIP6 accelerates the proliferation and invasion of cervical cancer by upregulating oncogenic YAP signaling.
Yang F; Li L; Zhang J; Zhang J; Yang L
Exp Cell Res; 2020 Nov; 396(1):112248. PubMed ID: 32853630
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model.
Hsu PC; Miao J; Huang Z; Yang YL; Xu Z; You J; Dai Y; Yeh CC; Chan G; Liu S; Urisman A; Yang CT; Jablons DM; You L
J Cell Mol Med; 2018 Jun; 22(6):3073-3085. PubMed ID: 29575527
[TBL] [Abstract][Full Text] [Related]
10. FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.
Elangovan IM; Vaz M; Tamatam CR; Potteti HR; Reddy NM; Reddy SP
Am J Respir Cell Mol Biol; 2018 May; 58(5):625-635. PubMed ID: 29112457
[TBL] [Abstract][Full Text] [Related]
11. MST4 kinase suppresses gastric tumorigenesis by limiting YAP activation via a non-canonical pathway.
An L; Nie P; Chen M; Tang Y; Zhang H; Guan J; Cao Z; Hou C; Wang W; Zhao Y; Xu H; Jiao S; Zhou Z
J Exp Med; 2020 Jun; 217(6):. PubMed ID: 32271880
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma.
Mohamed AD; Shah N; Hettmer S; Vargesson N; Wackerhage H
Sci Rep; 2018 Oct; 8(1):15674. PubMed ID: 30353028
[TBL] [Abstract][Full Text] [Related]
13. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
[TBL] [Abstract][Full Text] [Related]
14. OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ.
Zhang Z; Du J; Wang S; Shao L; Jin K; Li F; Wei B; Ding W; Fu P; van Dam H; Wang A; Jin J; Ding C; Yang B; Zheng M; Feng XH; Guan KL; Zhang L
Mol Cell; 2019 Jan; 73(1):7-21.e7. PubMed ID: 30472188
[TBL] [Abstract][Full Text] [Related]
15. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
Rozengurt E; Eibl G
World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295
[TBL] [Abstract][Full Text] [Related]
16. Platelet‑derived growth factor‑BB mediates pancreatic cancer malignancy via regulation of the Hippo/Yes‑associated protein signaling pathway.
Li T; Guo T; Liu H; Jiang H; Wang Y
Oncol Rep; 2021 Jan; 45(1):83-94. PubMed ID: 33416116
[TBL] [Abstract][Full Text] [Related]
17. YAP promotes breast cell proliferation and survival partially through stabilizing the KLF5 transcription factor.
Zhi X; Zhao D; Zhou Z; Liu R; Chen C
Am J Pathol; 2012 Jun; 180(6):2452-61. PubMed ID: 22632819
[TBL] [Abstract][Full Text] [Related]
18. YAP Orchestrates Heterotypic Endothelial Cell Communication via HGF/c-MET Signaling in Liver Tumorigenesis.
Thomann S; Weiler SME; Marquard S; Rose F; Ball CR; Tóth M; Wei T; Sticht C; Fritzsche S; Roessler S; De La Torre C; Ryschich E; Ermakova O; Mogler C; Kazdal D; Gretz N; Glimm H; Rempel E; Schirmacher P; Breuhahn K
Cancer Res; 2020 Dec; 80(24):5502-5514. PubMed ID: 33087321
[TBL] [Abstract][Full Text] [Related]
19. Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis.
Marquard S; Thomann S; Weiler SME; Bissinger M; Lutz T; Sticht C; Tóth M; de la Torre C; Gretz N; Straub BK; Marquardt J; Schirmacher P; Breuhahn K
Cell Commun Signal; 2020 Oct; 18(1):166. PubMed ID: 33097058
[TBL] [Abstract][Full Text] [Related]
20. YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma.
Yang C; Tan J; Zhu J; Wang S; Wei G
Oncotarget; 2017 Jun; 8(23):37154-37163. PubMed ID: 28415761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
